Literature DB >> 29937908

Hyperimmunoglobulin E syndrome.

Javad Ghaffari1.   

Abstract

Entities:  

Year:  2018        PMID: 29937908      PMCID: PMC5996575          DOI: 10.4103/jrms.JRMS_40_18

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


× No keyword cloud information.
Hashemi et al. recently published an article with title: Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities in your journal that it is a good paper.[1] Despite without limitation for searching, there are not a few of related papers in their working. Incidence of hyperimmunoglobulin E syndrome (HIGE) is 1/100,000–1/200,000. This syndrome divided into two groups including autosomal dominant with a mutation in signal transducer and activator of transcription-3 (chromosome 17, MIM = 147,060) Type 1 and autosomal recessive with a mutation in dedicator of cytokinesis 8 (chromosome 9, MIM = 243,700) (Type 2).[2] Mutations of autosomal recessive HIES-like disorders following: Tyrosine kinase 2 gene, encoded on chromosome 19p13.2 (MIM #611521) Phosphoglucomutase 3 gene, which encodes an enzyme in the biosynthesis of N-glycans (MIM #615816).[2] About skin manifestations of HIGE syndrome, we reported a boy (16 years old) of HIGE presented with skin psoriasis disease from 1 year ago. His history was recurrent infections including otitis media, pneumonia, diarrhea, and skin infection. Histologic finding was hyperkeratosis, parakeratosis of acanthotic epidermis with regular elongation of rete ridges. This is the first report of association or relation between hyperactive immunoglobulin E immunoglobulinemia and psoriasis disorder.[3] We reported another case of HIGE with recurrent infections and pneumatocele in the left and right of the lung. Because there were multiple large pneumatoceles, there was no possible surgery.[4] The role of bone marrow transplant has different results. Hematopoietic stem cell transplantation (HSCT) was done for different kinds of HIES, but information and experience about the long-term results of this therapy are little.[2] Recently, studies suggest that HSCT can improve immunologic parameters and reduce frequency and severity of infections although nonhematologic organ failures are not corrected.[5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  3 in total

1.  Psoriasis in hyper IgE syndrome - a case report.

Authors:  Javad Ghaffari; Saeed Abedian-Kenari; Maryam Ghasemi; Farzad Gohardehi
Journal:  Caspian J Intern Med       Date:  2013

2.  The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.

Authors:  Masakatsu Yanagimachi; Takashi Ohya; Tomoko Yokosuka; Ryosuke Kajiwara; Fumiko Tanaka; Hiroaki Goto; Takehiro Takashima; Tomohiro Morio; Shumpei Yokota
Journal:  J Clin Immunol       Date:  2016-04-18       Impact factor: 8.317

Review 3.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

  3 in total
  1 in total

1.  Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by negative dominance.

Authors:  Joëlle Khourieh; Peng Zhang; Franck Rapaport; Qian Zhang; Anne Puel; Vivien Béziat; Jean-Laurent Casanova; Bertrand Boisson; Takaki Asano; András N Spaan; Juan Li; Wei-Te Lei; Simon J Pelham; David Hum; Maya Chrabieh; Ji Eun Han; Antoine Guérin; Joseph Mackie; Sudhir Gupta; Biman Saikia; Jamila E I Baghdadi; Ilham Fadil; Aziz Bousfiha; Tanwir Habib; Nico Marr; Luckshman Ganeshanandan; Jane Peake; Luke Droney; Andrew Williams; Fatih Celmeli; Nevin Hatipoglu; Tayfun Ozcelik; Capucine Picard; Laurent Abel; Stuart G Tangye; Stéphanie Boisson-Dupuis
Journal:  J Exp Med       Date:  2021-06-17       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.